Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 recruiting3 with results

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT05628233Phase 2Completed

SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease

Role: lead

NCT05258773Phase 2Completed

Evaluation of the Presence of SENS-401 in the Perilymph

Role: lead

NCT06354010Recruiting

Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis

Role: lead

NCT05402813Recruiting

Natural History in Children Up to 16 Years with Mild to Profound Hearing Loss Due to Mutations in GJB2 / OTOF Genes

Role: lead

NCT06370351Phase 1Recruiting

A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations

Role: lead

NCT03603314Phase 2Completed

Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

Role: lead

NCT03110458Phase 2Completed

Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy

Role: lead

NCT03071003Phase 1Completed

A Study of SENS 401 in Healthy Subjects

Role: collaborator

All 8 trials loaded